SCHEMBL6985573

SCHEMBL6985573

CCCC(CC(=O)N1CCN(c2ccccc2)CC1)NC(=O)[C@H]1O[C@@H]1C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CASP1 P29466 1/20 0.46
KDM4E B2RXH2 2/20 0.44
CYP2C9 P11712 1/20 0.44
CYP2C19 P33261 1/20 0.44
MAPT P10636 6/20 0.43
LMNA P02545 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
ALDH1A1 P00352 3/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
USP2 O75604 1/20 0.41
HTR1A P08908 1/20 0.40
HTR7 P34969 1/20 0.40
GAA P10253 1/20 0.40
TFPI2 P48307 1/20 0.40
RAB9A P51151 1/20 0.40
KDM1A O60341 1/20 0.40
MAOA P21397 1/20 0.40
MAOB P27338 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6981304 0.91 CNR1 (0.44) CYP2C9CYP2C19MAPTMEN1KMT2A
SCHEMBL6981146 0.91 ALDH1A1 (0.45) LMNAALDH1A1MEN1KMT2AGAA
SCHEMBL6985160 0.91 MEN1 (0.48) KDM4ELMNANPSR1ALDH1A1MEN1
SCHEMBL6984525 0.89 GFER (0.46) KDM4ECYP2C9CYP2C19MAPTLMNA
SCHEMBL6981707 0.88 SMN1; SMN2 (0.43) MAPTLMNANPSR1ALDH1A1MEN1
SCHEMBL6978571 0.80 KMT2A (0.44) MAPTLMNANPSR1ALDH1A1MEN1
SCHEMBL6983402 0.79 NPC1 (0.54) KDM4ENPSR1ALDH1A1MEN1KMT2A
SCHEMBL6979227 0.78 GAA (0.39) NPSR1ALDH1A1KMT2AGAASMN1; SMN2
SCHEMBL6985559 0.75 CAPN1 (0.58) KDM4ENPSR1ALDH1A1GAACAPN1
SCHEMBL6982392 0.72 GRM5 (0.40) MAPTLMNANPSR1ALDH1A1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6551999-B1 For therapy and prophylaxis of angiogenesis associated with wound healing, inflammation, growth of tumor and the like; angiogenesis as seen in diabetic retinopathy, prematurity retinopathy, retinal venous occlusion, metastasis of tumors SENJU PHARMACEUTICAL CO., LTD. (JP) 2003-04-22 US disclosed
EP-0771565-B1 Angiogenesis inhibitor SENJU PHARMA CO (JP) 2003-01-02 EP disclosed
US-6214800-B1 ANGIOGENESIS INHIBITORS SENJU PHARMACEUTICAL CO., LTD. (JP) 2001-04-10 US disclosed
US-6057290-A ADMINISTERING A CYSTEINE PROTEASE INHIBITOR TO A PATIENT FOR INHIBITING ANGIOGENESIS SENJU PHARMACEUTICAL CO., LTD. (JP) 2000-05-02 US disclosed
EP-0928786-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-14 EP disclosed
EP-0927716-A1 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1999-07-07 EP disclosed
EP-0838460-A1 PIPERAZINE DERIVATIVES AND USE OF THE SAME Senju Pharmaceutical Co., Ltd. (JP) 1998-04-29 EP disclosed
EP-0771565-A2 Angiogenesis inhibitor Senju Pharmaceutical Co., Ltd. (JP) 1997-05-07 EP disclosed